MX2022005250A - Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. - Google Patents

Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.

Info

Publication number
MX2022005250A
MX2022005250A MX2022005250A MX2022005250A MX2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A MX 2022005250 A MX2022005250 A MX 2022005250A
Authority
MX
Mexico
Prior art keywords
capivasertib
acalabrutinib
lymphocytes
therapeutic combinations
malignant neoplasms
Prior art date
Application number
MX2022005250A
Other languages
English (en)
Spanish (es)
Inventor
Hannah Dry
Brandon Willis
Andrew Bloecher
Jerome Mettetal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022005250A publication Critical patent/MX2022005250A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022005250A 2019-11-04 2020-10-30 Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b. MX2022005250A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
MX2022005250A true MX2022005250A (es) 2022-06-08

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005250A MX2022005250A (es) 2019-11-04 2020-10-30 Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.

Country Status (14)

Country Link
US (1) US20220401442A1 (enExample)
EP (1) EP4054582B1 (enExample)
JP (1) JP7575454B2 (enExample)
KR (1) KR20220098175A (enExample)
CN (1) CN114728003B (enExample)
AU (1) AU2020381240C1 (enExample)
CA (1) CA3158321A1 (enExample)
DK (1) DK4054582T3 (enExample)
ES (1) ES3055126T3 (enExample)
FI (1) FI4054582T3 (enExample)
MX (1) MX2022005250A (enExample)
PL (1) PL4054582T3 (enExample)
PT (1) PT4054582T (enExample)
WO (1) WO2021089419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
KR20250105657A (ko) * 2022-11-15 2025-07-08 아스트라제네카 아베 카피바설팁과 베네토클락스의 치료적 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
EP3689878B1 (en) 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
KR20160090903A (ko) * 2013-12-04 2016-08-01 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
CN105979948A (zh) * 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
US20180353512A1 (en) * 2015-06-23 2018-12-13 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
CU20180059A7 (es) * 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2019058348A1 (en) * 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合

Also Published As

Publication number Publication date
CN114728003B (zh) 2025-01-28
DK4054582T3 (da) 2025-12-01
US20220401442A1 (en) 2022-12-22
WO2021089419A1 (en) 2021-05-14
ES3055126T3 (en) 2026-02-10
PL4054582T3 (pl) 2026-02-16
CA3158321A1 (en) 2021-05-14
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
EP4054582B1 (en) 2025-09-03
PT4054582T (pt) 2025-12-10
CN114728003A (zh) 2022-07-08
EP4054582A1 (en) 2022-09-14
FI4054582T3 (fi) 2025-12-04
AU2020381240B2 (en) 2023-09-07
AU2020381240A1 (en) 2022-06-23
AU2020381240C1 (en) 2024-02-15
KR20220098175A (ko) 2022-07-11

Similar Documents

Publication Publication Date Title
CL2022001671A1 (es) Inhibidores de sos1
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
MX2019007416A (es) Derivados de benzooxazol como inmunomoduladores.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2019000189A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso. (divisional solicitud 201801481)
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
MX2016013182A (es) Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
EA201692176A1 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
CL2019002240A1 (es) Dendrímeros terapéuticos.
EA202191519A1 (ru) Модуляторы trex1
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CO2020016151A2 (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CL2022001661A1 (es) Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos